Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanolimumab plus CHOP in CD4-positive peripheral T-cell lymphoma
2006-004516-51Phase 2Terminated
- Sponsor
- Genmab
- Start
- Oct 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zanolimumab in peripheral T-cell lymphoma (PTCL), sponsored by Genmab. Primary endpoint: Dose-Limiting Toxicities in Cycle 1. Started Oct 2006; status: terminated.
02
Drugs
zanolimumab
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on 2006-004516-51.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004516-51.